Fig. 2: PD-1 blockade enhances T cell function.
From: CS1003, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer therapy
a–c The functionality of CS1003 and pembrolizumab in enhancing T cell responses was assessed using MLR, and T cell proliferation ([3H]-TDR incorporation) and effector function (IFN-γ production) were quantified. d–e CS1003 reversed Treg cell suppressive function in the MLR assay. **P < 0.01, ***P < 0.001.
